Estimating the Lifetime Benefits of Treatments for Heart Failure

João Pedro Ferreira, MD, PHD; Kieran F. Docherty, MBCHB; Susan Stienen, MD, PHD; Pardeep S. Jhund, MBBCH, PHD; Brian L. Claggett, PHD; Scott D. Solomon, MD; Mark C. Petrie, MBCHB; John Gregson, PHD; Stuart J. Pocock, PHD; Faiez Zannad, MD, PHD; John J.V. McMurray, MD


JACC Heart Fail. 2020;8(12):984-995. 

In This Article


RMST event-free (and overall) survival estimates provide a complementary means of evaluating the effect of therapy in relation to age and risk. It provides a clinically useful metric that should be routinely reported and used to explain the potential long-term benefits of a given treatment, especially to younger and less symptomatic patients who might be more reluctant to adhere to a treatment for life.